Trial Profile
A Phase I/II STudy of Oxaliplatin, Oral Capecitabine and Sorafenib in Patients With Advanced Pancreatic and Biliary Carcinoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Sorafenib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Oct 2010 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
- 15 Oct 2010 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 19 May 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.